Ipca Laboratories stock
IPCALAB.NSNSEIpca Laboratories Limited, HealthcareISIN INE571A01038
70Score 70 out of 100, Strong
Price and trend
75 / 100
Price history
+42% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 12% above it.
Since January 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 40).
The price is 5.5% below its 52-week high. Largest decline in 20 years: 61% (July 2007 to March 2009).
Chart figures for advanced users
- SMA 50$20.74
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$18.09
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)40
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$13.90
- The lowest closing price of the last twelve months.
- Resistance$21.45
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Ipca Laboratories Limited belongs to the Drug Manufacturers (Specialty & Generic) industry (India) and, with a market value of $5.14B, is number 42 of 78 companies in its industry on MEQIRI.
- In fiscal 2026 it reported revenue of $1.03B (up 7.9% year on year) and earnings of $121.79M (up 54.7%).
- For fiscal 2027, analysts expect on average revenue of $1.18B (up 14.2%) and adjusted earnings per share of $0.64 (up 29.2%).
Show more
- MEQIRI Score 70 out of 100 (Strong): rank 141 of 714 in Healthcare, median 53.
- The P/E is 34.4 (Drug Manufacturers (Specialty & Generic) median 32.6, own median of recent years 35.3).
- Our model puts fair value at $18.07, with the price 14% above it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Consistently profitableProfit in all 10 fiscal years from 2017 to 2026.Fundamentals 76
- More cash than debtCash $127.86M, financial debt $86.32M.Stability 89
- High return on capitalReturn on invested capital 19.8% in fiscal 2026, Drug Manufacturers (Specialty & Generic) median 11.3%.Profitability 75
Weaknesses
- Margin fallingOperating margin 24.2%, average of the prior years 39.3% (to 2025).
Its standout strengths are stability and momentum, while valuation holds the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 72 to 70.
Fundamentals are strong, with stable profits.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk not measured
How well MEQIRI warnsFor stocks from Japan, China, Hong Kong, Taiwan, Korea, Canada, India and Brazil we only show crash risk once a separate backtest shows that it warns as well there as in the US and Europe.
Valuation
Valuation signal
Fairly valuedClosing price of 11 Nov 2026, used by the daily score.
In our model the price counts as cheap below $13.90 and expensive above $25.82 (uncertainty medium, based on the price swings of the past year).
The two parts of the fair value come to $16.92 (cash-flow model) and $19.23 (industry comparison), and the gap between them shows how uncertain the estimate is. The price is slightly above both parts; given how much the stock swings, that still counts as fair.
Calculated with a cost of equity of 12.6%. At 13.6% the fair value would be $16.72, at 11.6% it would be $20.01.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (32.6).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 12% on the twelve months before. Revenue has grown strongly since 2007, at around 13% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2026: gross 64%, operating 24%, net 12%.
Debt & balance sheet
latest quarterThe balance sheet is solid, with low debt and comfortable interest coverage.
Earnings
- Next earnings
- 17 Feb 2027in 97 days
- Last reported
- 5 Nov 2026EPS reported $0.16 (expected $0.17)below expectations
Analyst estimates
Earnings estimates have barely changed since 24 Oct 2026.
- Earnings per share
- $0.640.0%
- Revenue
- $1.18B0.0%
- Earnings per share
- $0.750.0%
- Revenue
- $1.31B0.0%
MEQIRI has stored the estimates since 24 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
What happened at Ipca Laboratories
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 70
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Drug Manufacturers (Specialty & Generic)
The next larger and next smaller companies by market value
- China Resources Sanjiu Medical & Pharmaceutical000999.SZ $6.25B73
- Apotex HealthAPTX.TO $5.78B70
- Gland PharmaGLAND.NS $5.75B70
- Sumitomo Pharma4506.T $5.45B57
- Shenzhen Salubris Pharmaceuticals002294.SZ $5.03B53
- Laboratorios Farmaceuticos RoviROVI.MC $4.02B82
- Siegfried HoldingSFZN.SW $3.77B55
- Bausch Health CompaniesBHC $3.13B61
ETFs that hold Ipca Laboratories
Held by 12 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| iShares MSCI EM Small Cap UCITS ETFEUNI | 0.19% | 0.74% | €274.03M |
| Vanguard FTSE Emerging Markets UCITS ETF (USD) AccumulatingVFEA | 0.03% | 0.17% | €5.24B |
| iShares MSCI EM IMI Screened UCITS ETF USD (Acc)AYEM | 0.02% | 0.18% | €5.15B |
Show 5 more
| iShares Core MSCI EM IMI UCITS ETFIS3N | 0.02% | 0.18% | €37.17B |
| Amundi Prime All Country World UCITS ETF AccWEBN | 0.00% | 0.07% | €8.65B |
| Vanguard ESG Global All Cap UCITS ETF (USD) AccumulatingV3AA | 0.00% | 0.24% | €1.69B |
| Vanguard FTSE All-World UCITS ETF (USD) AccumulatingVWCE | 0.00% | 0.14% | €79.59B |
| Vanguard FTSE Global All-Cap UCITS ETF Accum USDVGLA | 0.00% | 0.07% | €3.9B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2026, period end 31 Mar 2026
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 11 Nov 2026 ($1 = ₹93.6946)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong, published since 7 Nov 2026 (in the score history since 31 Oct 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.